{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:18:13Z","timestamp":1790864293330,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Liver metastases from neuroendocrine tumors (NETs) are an accepted indication for liver transplantation (LT). Despite strict patient selection, post-LT recurrence is observed in 30%\u201350% of cases. Postrecurrence survival is poorly investigated as well as factors influencing postrecurrence outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Consecutive patients treated at a single institution for post-LT recurrence of NET between January 1, 2004, and December 31, 2018, were included. Baseline patients\u2019 characteristics, data on the primary tumor, pretransplant therapies, posttransplant recurrence and treatments, and long-term outcomes were prospectively collected and retrospectively analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Thirty-two patients presented with post-LT NET recurrence occurring 82.9 mo (interquartile range, 29.4\u2013119.1 mo) from LT, and the most common sites were abdominal lymph nodes (59.4%), peritoneum (6.3%), and lungs (6.3%). Fourteen patients (43.8%) underwent surgery with radical intent. Five- and 10-y survival after recurrence were 76.3% and 45.5%, respectively. Only time from LT to recurrence had a significant impact on postrecurrence survival, being 5-y overall survival 89.5% versus 0% for patients recurring &gt;24 mo after LT versus \u226424 mo, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001). Moreover, for patients with Ki-67 monoclonal antibody staining &gt;2% at recurrence, 5 y overall survival was 87.5% versus 0% for those undergoing surgery versus locoregional or systemic treatments (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.011).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>The presented results, although based on a retrospective and relatively small series, show that excellent long-term survival is observed after post-LT NET recurrence, particularly in those patients recurring long after LT (&gt;24 mo). An aggressive surgical treatment might result in a new chance of cure for a selected subgroup of patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003802","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T10:09:58Z","timestamp":1619604598000},"page":"2579-2586","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors"],"prefix":"10.1097","volume":"105","author":[{"given":"Carlo","family":"Sposito","sequence":"first","affiliation":[{"name":"HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy."},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Elisa","family":"Rossi","sequence":"additional","affiliation":[{"name":"HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy."},{"name":"Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Monteleone","sequence":"additional","affiliation":[{"name":"HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgelina","family":"Coppa","sequence":"additional","affiliation":[{"name":"HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bongini","sequence":"additional","affiliation":[{"name":"HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[{"name":"Pathology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Bhoori","sequence":"additional","affiliation":[{"name":"HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[{"name":"HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy."},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1053\/j.gastro.2005.03.078","article-title":"Enteroendocrine tumors other than carcinoid: a review of clinically significant advances.","volume":"128","author":"Warner","year":"2005","journal-title":"Gastroenterology"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site.","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.","volume":"12","author":"Panzuto","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","article-title":"Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database.","volume":"24","author":"Fairweather","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cncr.28760","article-title":"Therapeutic strategies for neuroendocrine liver metastases.","volume":"121","author":"Frilling","year":"2015","journal-title":"Cancer"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11154-017-9439-7","article-title":"The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: pros and cons.","volume":"18","author":"Sposito","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/ajt.13831","article-title":"The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors.","volume":"16","author":"Mazzaferro","year":"2016","journal-title":"Am J Transplant"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/TP.0b013e3182081312","article-title":"Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis.","volume":"91","author":"M\u00e1th\u00e9","year":"2011","journal-title":"Transplantation"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/SLA.0b013e31828ee17c","article-title":"Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study.","volume":"257","author":"Le Treut","year":"2013","journal-title":"Ann Surg"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jso.23973","article-title":"Liver transplantation for metastatic neuroendocrine tumors: outcomes and prognostic variables.","volume":"112","author":"Sher","year":"2015","journal-title":"J Surg Oncol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2008.02233.x","article-title":"Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report.","volume":"8","author":"Le Treut","year":"2008","journal-title":"Am J Transplant"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1210\/jc.2008-0459","article-title":"Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.","volume":"93","author":"Leboulleux","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.hpb.2018.10.005","article-title":"Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.","volume":"21","author":"Goldaracena","year":"2019","journal-title":"HPB (Oxford)"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2007.07.004","article-title":"Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?","volume":"47","author":"Mazzaferro","year":"2007","journal-title":"J Hepatol"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/00007890-199811270-00007","article-title":"Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients.","volume":"66","author":"Lehnert","year":"1998","journal-title":"Transplantation"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00007890-200202150-00012","article-title":"Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.","volume":"73","author":"Rosenau","year":"2002","journal-title":"Transplantation"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1245\/s10434-013-3449-9","article-title":"Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer.","volume":"21","author":"Hagness","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0000000000001894","article-title":"Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics.","volume":"266","author":"Bodzin","year":"2017","journal-title":"Ann Surg"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jhep.2013.02.026","article-title":"Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.","volume":"59","author":"Sposito","year":"2013","journal-title":"J Hepatol"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00432-011-1014-0","article-title":"An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma.","volume":"137","author":"Cheng","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jhep.2013.03.029","article-title":"Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence.","volume":"59","author":"Toso","year":"2013","journal-title":"J Hepatol"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1245\/s10434-014-3523-y","article-title":"Liver transplantation for unresectable neuroendocrine tumor liver metastases.","volume":"21","author":"Rossi","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12020-017-1364-8","article-title":"KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?","volume":"57","author":"Grillo","year":"2017","journal-title":"Endocrine"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T16:12:32Z","timestamp":1749312752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003802","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,22]]}}}